example 10 [CN110740999A]   Click here for help

GtoPdb Ligand ID: 12952

Synonyms: compound 40 [PMID: 34323489] [4]
Compound class: Synthetic organic
Comment: This chemical structure was extracted from a patent claiming fourth generation EGFR inhibitors [2]. Based on a chemical structure that was submitted to the Cambridge Crystallographic Data Centre (Deposition number 2261855), and in the absence of a disclosed name-to-structure, we predict that this is likely to be the clinical lead EGFR inhibitor BBT-176 (or is closely related to it) as written about in [3].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 11
Hydrogen bond donors 3
Rotatable bonds 9
Topological polar surface area 122.28
Molecular weight 601.17
XLogP 1.65
No. Lipinski's rules broken 2
Click here for help
Canonical SMILES CN1CCN(CC1)C2CCN(CC2)C3=CC=C(C(=C3)OC)NC4=NC(=C(C=N4)Cl)NC5=C(C=CC=C5)NS(=O)(=O)C
InChI InChI=1S/C28H37ClN8O3S/c1-35-14-16-37(17-15-35)20-10-12-36(13-11-20)21-8-9-25(26(18-21)40-2)32-28-30-19-22(29)27(33-28)31-23-6-4-5-7-24(23)34-41(3,38)39/h4-9,18-20,34H,10-17H2,1-3H3,(H2,30,31,32,33)
1. He J, Zhou Z, Sun X, Yang Z, Zheng P, Xu S, Zhu W. (2021)
The new opportunities in medicinal chemistry of fourth-generation EGFR inhibitors to overcome C797S mutation.
Eur J Med Chem, 210: 112995. [PMID:33243531]
2. Lee KH, Xin R, Cui J, Cai Z, Choi HJ, Zheng M, Tian B, Zhao B, Park C, Jin H, Daugirala KB. (2020)
N2, N4-diphenylpyrimidine-2, 4-diamine derivative, process for producing the same, and pharmaceutical composition for preventing or treating cancer comprising the same as active ingredient.
Patent number: CN110740999A. Assignee: Korea Institute Of Chemistry Korea Research Institute of Chemical Technology KRICT. Priority date: 12/06/2018. Publication date: 31/01/2020.
3. Lim SM, Fujino T, Kim C, Lee G, Lee YH, Kim DW, Ahn JS, Mitsudomi T, Jin T, Lee SY. (2023)
BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non-Small Cell Lung Cancer.
Clin Cancer Res, 29 (16): 3004-3016. [PMID:37249619]
4. Shaikh M, Shinde Y, Pawara R, Noolvi M, Surana S, Ahmad I, Patel H. (2022)
Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer.
J Med Chem, 65 (2): 1008-1046. [PMID:34323489]